Next-generation immune checkpoint inhibitors as promising functional molecules in cancer therapeutics

Excerpt

Cancer is a devastating disease that demands expensive treatment and follow-up patient care. The current intention of cancer therapeutics is to eradicate or slow down the aggressive behavior of cancerous cell infiltration in to systemic circulation and confine its progression. As per the International Agency for Research on Cancer (IARC), by 2040, the worldwide cancer cases are expected to be 27.5 million new cancer cases and 16.3 million deaths globally. The increasing incidence of cancer cases is expected to drive the need for advanced cancer therapies for the effective treatment of patients. The surge in incidence of cancer cases is estimated to accelerate global market expansion of cancer therapeutics in the forthcoming years. A market study published in August 2021 by CISION PR Newswire and Global Industry Analysts Inc. stated that the global market for cancer therapies continuously demonstrated robust growth. By 2024 this segment will touch ~ 204.2 billion US dollar (USD) with 9.7% of compounded annual growth rate (CAGR), whereas Precedence Research quoted that the oncology market size will reach 581.25 billion USD by 2030 with 8.2% of CAGR. North America is going to hold the highest market share followed by Europe region globally. …